On August 4, as it posted quarterly results, Mallinckrodt, a multi-billion-dollar manufacturer of niche medical products focused on the US market, informed the New York Stock Exchange that it was considering Chapter 11 bankruptcy – the American equivalent of an examinership. In the following week, its stock, already near an all-time low, lost over a third of its value. The company has been facing an avalanche of litigation, compounded by shifts in demand for its drugs and devices targeting rare diseases, pain, disorders of the immune and digestive systems, and respiratory distress. Mallinckrodt’s lawyers are facing an uphill battle, and…

Want to continue reading?

Join today with an Annual membership and get full access to The Currency for just €200 (68c per day) or try monthly membership for just €5 for your first month.

Subscribe

Cancel at any time.

Are you already a member? .